DOCSLIB.ORG

Comparative Assessment of Image Quality for Coronary CT Angiography with Iobitridol and Two Contrast Agents with Higher Iodine Concentrations: Iopromide and Iomeprol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Assessment of Image Quality for Coronary CT Angiography with Iobitridol and Two Contrast Agents with Higher Iodine Concentrations: Iopromide and Iomeprol Eur Radiol (2017) 27:821–830 DOI 10.1007/s00330-016-4437-9 CONTRAST MEDIA Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial Stephan Achenbach1 & Jean-François Paul2 & François Laurent3,4 & Hans-Christoph Becker5 & Marco Rengo6 & Jerome Caudron7 & Sebastian Leschka8 & Olivier Vignaux9 & Gesine Knobloch10 & Giorgio Benea11 & Thomas Schlosser12 & Jordi Andreu13 & Beatriz Cabeza14 & Alexis Jacquier15 & Miguel Souto16 & Didier Revel17 & Salah Dine Qanadli18 & Filippo Cademartiri19 & on behalf of the X-ACT Study Group Received: 7 August 2015 /Revised: 19 May 2016 /Accepted: 23 May 2016 /Published online: 7 June 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract attenuation, signal and contrast to noise ratio (SNR, CNR). Objectives To demonstrate non-inferiority of iobitridol 350 Patients were considered evaluable if no segment had a for coronary CT angiography (CTA) compared to higher score of 0. iodine content contrast media regarding rate of patients Results Per-patient, the rate of fully evaluable CT scans evaluable for the presence of coronary artery stenoses. was 92.1, 95.4 and 94.6 % for iobitridol, iopromide and Methods In this multicentre trial, 452 patients were randomized iomeprol, respectively. Non-inferiority of iobitridol over to receive iobitridol 350, iopromide 370 or iomeprol 400 and the best comparator was demonstrated with a 95 % CI underwent coronary CTA using CT systems with 64- of the difference of [-8.8 to 2.1], with a pre-specified detector rows or more. Two core lab readers assessed 18 non-inferiority margin of -10 %. Although average at- coronary segments per patient regarding image quality tenuation increased with higher iodine concentrations, (score 0 = non diagnostic to 4 = excellent quality), vascular average SNR and CNR did not differ between groups. * Stephan Achenbach 8 Department of Radiology, Saint Gallen Hospital, Saint [email protected] Gallen, Switzerland on behalf of the X-ACT Study Group 9 Department of Radiology, Cochin Hospital, Paris, France 10 Department of Radiology, La Charité, Berlin, Germany 1 Department of Cardiology, Friedrich-Alexander-Universität 11 Ospedale del Delta, Ferrara, Italy Erlangen-Nürnberg, Ulmenweg 18, 91054 Erlangen, Germany 12 2 Department of Radiology, Centre Chirurgical Marie Lannelongue, Le Elisabeth-Krankenhaus Hospital, Essen, Gerrmany Plessis Robinson, France 13 Hospital Vall d’Hebron, Barcelona, Spain 3 University of Bordeaux, Centre de Recherche Cardio-Thoracique de 14 Hospital Clinico San Carlos, Madrid, Spain Bordeaux, U1045, F-33000 Bordeaux, France 15 Department of Radiology, La Timone Adult Hospital, 4 ’ CHU de Bordeaux, Service d Imagerie Thoracique et Marseille, France Cardiovasculaire, F-33600 Pessac, France 16 Complejo Hospitalario Universitario, Santiago de Compostela, Spain 5 Department of Clinical Radiology, University Hospital Grosshadern, Munich, Germany 17 Department of Radiology, Louis Pradel Hospital, Lyon, France 6 Department of Radiological Sciences, Oncology and Pathology, 18 Department of Radiology, University of Lausanne, Sapienza – University of Rome, ICOT Hospital, Latina, Italy Lausanne, Switzerland 7 Department of Radiology, University Hospital of Rouen, 19 Department of Radiology, Giovanni XXIII Hospital, Monastier di Rouen, France Treviso, Italy 822 Eur Radiol (2017) 27:821–830 Conclusions With current CT technology, iobitridol 350 mg inferiority of iobitridol 350 compared to the best of the two iodine/ml is not inferior to contrast media with higher iodine comparators in terms of image quality and interpretability as concentrations in terms of image quality for coronary stenosis measured by the rate of patients with CT scans evaluable for the assessment. identification of coronary artery stenosis. Key Points • Iodine concentration is an important parameter for image quality in coronary CTA. Material and methods • Contrast enhancement must be balanced against the amount of iodine injected. Study design and patient enrolment conditions • Iobitridol 350 is non-inferior compared to CM with higher iodine concentrations. This study was a non-inferiority, multicentre, randomized, • Higher attenuation with higher iodine concentrations, but no double-blind, clinical trial on three parallel groups. Patients SNR or CNR differences. were included in 23 centres from five countries between November 2010 and September 2012 and randomized on a Keywords Coronary computed tomography angiography . 1:1:1 ratio to undergo clinically indicated coronary CTA after Image quality . Contrast media . Iodine concentration . Safety injection of iobitridol, iopromide or iomeprol. The study was approved by each local ethics committees and the National Health Authorities. Written informed consent was obtained Introduction from each participating patient. Symptomatic adult patients with suspected coronary artery Coronary computed tomography angiography (coronary disease (CAD), and scheduled for coronary CT angiography CTA) has become widely accepted in clinical practice [1–3]. were enrolled in this study. Patients could not be included if Technology progress has increased the robustness and diag- they had both a contraindication to β-blocker medications and a nostic performance of coronary CTA, resulting in improved baseline heart rate above 65 beats per minute (bpm). Additional image quality and lower radiation exposure [4–9]. reasons for exclusion were the presence of arrhythmias or non- The protocols for administration of intravenous contrast me- sinus rhythm, coronary artery bypass grafts or stents, artificial dia (CM) are of major importance in coronary CTA, usually heart valves, moderate to severe aortic valve stenosis, hyperthy- performed to identify coronary artery stenoses but also calcified roidism, clinical instability, severe renal failure or previous in- and non-calcified plaques [10–13]. The optimal intravascular jection of any CM within 48 hours prior to the study. attenuation for coronary CT angiography is under debate [14, 15]. Several publications suggested that adequate opacification Patient preparation of the vessel lumen for the simultaneous identification of both calcified and non-calcified plaques requires a careful contrast β-blockers were mandatory if heart rate was >65 bpm. The injection protocol that achieves a lumen opacification of at least specific drug, dose and mode of administration were selected 300 HU [15–17]. In principle, the Iodine Delivery Rate (IDR) according to site routine practice. A minimum dose of 0.8 mg should be the reference when using different compounds for of sublingual nitroglycerine spray was mandatory immediate- intraluminal enhancement [18]. However, most centres do not ly before the CT examination. Other pre-medication was per- use this approach in clinical practice. mitted, given according to operator preference, and recorded. Higher iodine concentration of the injected CM is associated with higher attenuation [16, 19]. However, increasing the total Injection of contrast media amount of iodine injected could raise safety issues for patients at risk such as contrast induced nephropathy [20–22]. For each patient, one of three CM was delivered intravenous- Therefore, adequate contrast enhancement must be balanced ly: Iobitridol 350 mg iodine/ml (Xenetix®, Guerbet, Aulnay- against the amount of iodine injected. Several studies have ad- sous-Bois, France), iopromide 370 mg/ml (Ultravist®, Bayer dressed the level of attenuation with different CM [14, 23, 24], Healthcare, Berlin, Germany) and iomeprol 400 mg/ml but few studies evaluated the impact of their concentration on (Iomeron®, Bracco, Milan, Italy). Delivered volume and de- image quality [25]. Furthermore, whether differences less than livery rate of CM was consistent for the three CM but varied 50 mg/ml of iodine concentration could affect image quality according to patient body weight (BW): 60 ml injected at remains to be clarified. The present study compared a CM with 4 ml/s for a BW <60 kg, 75 ml at 5 ml/s for a BW between iodine concentration of 350 mg iodine/ml (iobitridol) to two 60 and 80 kg, 90 ml at 6 ml/s for a BW >80 kg. Therefore, the CM with higher iodine concentrations (iopromide 370 mg/ml iodine-delivery rate was lowest for iobitridol. CM was and iomeprol 400 mg/ml) for coronary CTA. The main objec- warmed and injections were followed by a 100 % saline flush tive of the study was to demonstrate the statistical non- of 75 ml administered at the same rate as the CM. Eur Radiol (2017) 27:821–830 823 Scan protocol Society of Cardiovascular Computed Tomography (SCCT) cor- onary segmentation model [29] (4 = excellent quality, full con- All coronary CTAs were performed on systems with at least 64 fidence without any doubts concerning the presence/absence of detector rows (single or dual source). The tube voltage was luminal stenosis; 3 = good quality, confidence concerning the adapted to the patient’s BW depending on the equipment used presence/absence of luminal stenosis; 2 = moderate quality, rel- in the site: either 120 kVp for all patients or 120 kVp for BW ative confidence, with minor doubts concerning the presence/ ≥80 kg and 100 kVp for BW <80 kg. Each patient first received absence of luminal stenosis; 1 = poor quality, some doubts a non-contrast acquisition for the quantification of coronary concerning the presence/absence
Load more

Recommended publications
  • 201277Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201277Orig1s000 OTHER REVIEW(S) PMR/PMC Development Template This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: DARRTS Set #1743-1 A study that will examine the safety of Gadavist in new born and neonates animals, following a single dose and limited repeated dose administrations. The study will provide safety data assessing mortality, toxicities, and potential reversibility of observed clinical and histopathological findings. The study will also examine the pharmacokinetics of Gadavist including tissue deposition of Gadolinium. PMR/PMC Schedule Milestones: Final Protocol Submission: May, 2011 Study/Trial Completion: January, 2012 Final Report Submission: June, 2012 Other: 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval (I removed this check on the nonclinical form) Prior clinical experience indicates safety Small subpopulation affected (I removed this check on the nonclinical form) Theoretical concern Other Proposed nonclinical study will evaluate the safety of Gadavist in a non clinical animal model prior to clinical exposure in view of known risk of NSF in adults especially those with renal impairment. 2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.” ReferencePMR/PMC ID: 2918081Development Template Last Updated 3/14/2011 Page 1 of 4 To evaluate the safety of Gadavist in newborn and neonate animals.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Iodinated Pharmaceuticals As Precursors to Total Organic
    IODINATED PHARMACEUTICALS AS PRECURSORS TO TOTAL ORGANIC HALOGEN FORMATION IN THE PRESENCE OF CHLORINATED OXIDANTS AND ABSENCE OF NATURAL ORGANIC MATTER A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Pushpita Kumkum August, 2013 IODINATED PHARMACEUTICALS AS PRECURSORS TO TOTAL ORGANIC HALOGEN FORMATION IN THE PRESENCE OF CHLORINATED OXIDANTS AND ABSENCE OF NATURAL ORGANIC MATTER Pushpita Kumkum Thesis Approved: Accepted: _____________________________ _____________________________ Advisor Department Chair Dr. Stephen Duirk Dr. Wieslaw Binienda _____________________________ _____________________________ Committee Co-Chair Dean of the College Dr. Christopher Miller Dr. George K. Haritos _____________________________ _____________________________ Committee Member Dean of the Graduate School Dr. Chelsea Monty Dr. George R. Newkome _____________________________ Date ii ABSTRACT The aim of this study was to investigate iodinated pharmaceuticals as potential precursors to total organic halogen (TOX) formation in the presence of chlorinated oxidants (i.e., aqueous chlorine and monochloramine) and without NOM present. The reaction mechanism of aqueous chlorine and monochloramine with iopamidol, an iodinated x-ray contrast media (ICM), as a primary contributor of iodide in the formation of total organic iodide (TOI), the precursor to the formation of extremely toxic iodinated- DBPs, was evaluated. Reaction with other ICM with chlorinated oxidants was also investigated. The traditional TOX method was modified to measure total organic chloride (TOCl), total organic bromide (TOBr), as well as TOI. The aqueous chlorination of iopamidol, iomeprol, iopromide, iohexol and Na- diatrizoate was studied in the pH range 6.5-9 and at 25±1 °C. Under these conditions, iopamidol was transformed releasing iodide into aqueous phase.
    [Show full text]
  • In Vivo X-Ray Computed Tomographic Imaging of Soft Tissue with Native, Intravenous, Or Oral Contrast
    Sensors 2013, 13, 6957-6980; doi:10.3390/s130606957 OPEN ACCESS sensors ISSN 1424-8220 www.mdpi.com/journal/sensors Review In vivo X-Ray Computed Tomographic Imaging of Soft Tissue with Native, Intravenous, or Oral Contrast Connor A. Wathen 1, Nathan Foje 2, Tony van Avermaete 2,3, Bernadette Miramontes 2,3, Sarah E. Chapaman 4, Todd A. Sasser 2,5, Raghuraman Kannan 6, Steven Gerstler 7 and W. Matthew Leevy 1,4,8,* 1 Department of Biological Sciences, 100 Galvin Life Sciences Center, University of Notre Dame, Notre Dame, IN 46556, USA; E-Mail: [email protected] 2 Department of Chemistry and Biochemistry, 236 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA; E-Mails: [email protected] (N.F.); [email protected] (T.V.A.); [email protected] (B.M.); [email protected] (T.A.S.) 3 Penn High School, 55900 Bittersweet Road, Mishawaka, IN 46545, USA 4 Notre Dame Integrated Imaging Facility, Notre Dame, IN 46556, USA; E-Mail: [email protected] 5 Bruker-Biospin Corporation, 4 Research Drive, Woodbridge, CT 06525, USA 6 Department of Radiology, University of Missouri, Columbia, MO 65212, USA; E-Mail: [email protected] 7 Saint Joseph Regional Medical Center, Mishawaka, IN 46545, USA; E-Mail: [email protected] 8 Harper Cancer Research Institute, A200 Harper Hall, Notre Dame, IN 46530, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 27 March 2013; in revised form: 16 May 2013 / Accepted: 23 May 2013 / Published: 27 May 2013 Abstract: X-ray Computed Tomography (CT) is one of the most commonly utilized anatomical imaging modalities for both research and clinical purposes.
    [Show full text]
  • The Risk of Contrast Media-Induced Ventricular Fibrillation Is Low in Canine Coronary Arteriography with Ioxilan
    FULL PAPER Surgery The Risk of Contrast Media-Induced Ventricular Fibrillation is Low in Canine Coronary Arteriography with Ioxilan Kazuhiro MISUMI, Oki TATENO, Makoto FUJIKI, Naoki MIURA and Hiroshi SAKAMOTO Department of Veterinary Medicine, Kagoshima University, 21–24 Korimoto 1-chome, Kagoshima 890–0065, Japan (Received 5 August 1999/Accepted 28 December 1999) ABSTRACT. Previous studies have proposed that sodium supplement to nonionic contrast media (CM) can decrease the risk of ventricular fibrillation (VF). This study was designed to compare the occurence of VF induced by ioxilan (containing 9 mmol/LNa+) with other nonionic CMs. After wedging a catheter in the right coronary artery, test solutions including ioxilan, ioversol, iomeprol, and iopromide were infused for 30 sec at the rate of 0.4 ml/sec or until VF occurred. Then, incidence of VF, contact time (i.e. the time required to produce VF), and QTc were measured. Also, the CMs other than ioxilan were investigated at sodium levels adjusted to 9 and 20 mmol/L Na+. The incidence of VF with ioxilan (0% ) was the lowest of all. In the other CMs, the incidence decreased in accordance with increase of sodium. Iomeprol and iopromide showed significant reduction of VF incidence at the sodium level of 20 mmol/L. The higher sodium supplements also prolonged the contact times. The increase of QTc was the greatest in ioxilan. Ioxilan has the least arrythmogenic property among the current low-osmolality nonionic CMs. This property might be attributable to an optimal sodium concentration of 9 mmol/L in the CM.—KEY WORDS: contrast media, coronary arteriography, ioxilan, ventricular fibrillation.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Structure and Properties of X-Ray Contrast Media
    STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA Optimal use of CM in radiology requires a knowl- edge of the nature and relevant properties of the available substances. This chapter describes the properties of currently used and newly developed contrast-giving agents that infuence their behav- ior in the human body, their side effects, and their practical utility. The main X-ray contrast agents in use today are insoluble barium sulfate for the diagnostic evalu- ation of the GI tract and water-soluble CM for the radiological assessment of the different vascular systems, body cavities and organs. In addition, a water-soluble CM based on tri-iodobenzene is the alternative agent of choice for oral use when bari- um sulfate is contraindicated. Barium Sulfate Barium is used in the form of the insoluble sulfate for radiography of the GI tract. If perforation is suspected, however, only water-soluble, iodinated agents (Gastrografn, Ultravist-370) can be used since the body is virtually incapable of eliminating barium sulfate once it has entered the peritoneum. Barium sulfate is available either as a powder to be prepared directly before use or as a ready-to-use suspension. For double-contrast examinations (fll- ing of the lumen with gas, coating of the wall with barium sulfate), barium sulfate is either mixed with a carbon dioxide additive, or a gas-forming agent is taken in addition. © The Author(s) 2018 20 U. Speck, X-Ray Contrast Media, https://doi.org/10.1007/978-3-662-56465-3_3 Common to all barium preparations is concentra- tion of barium sulfate which may diluted according to the needs of the examination.
    [Show full text]
  • Analytical Interference by Contrast Agents in Biochemical Assays
    Hindawi Contrast Media & Molecular Imaging Volume 2017, Article ID 1323802, 8 pages https://doi.org/10.1155/2017/1323802 Research Article Analytical Interference by Contrast Agents in Biochemical Assays Sigrid Otnes,1 Niels Fogh-Andersen,2 Janne Rømsing,1 and Henrik S. Thomsen3 1 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 2Department of Clinical Biochemistry, Copenhagen University Hospital Herlev, Herlev, Denmark 3Department of Radiology, Copenhagen University Hospital Herlev, Herlev, Denmark Correspondence should be addressed to Henrik S. Thomsen; [email protected] Received 5 January 2017; Accepted 30 March 2017; Published 10 April 2017 Academic Editor: Giuseppe Rubini Copyright © 2017 Sigrid Otnes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To provide a clinically relevant overview of the analytical interference by contrast agents (CA) in laboratory blood test measurements. Materials and Methods. The effects of five CAs, gadobutrol, gadoterate meglumine, gadoxetate disodium, iodixanol, and iomeprol, were studied on the 29 most frequently performed biochemical assays. One-day-old plasma, serum, and whole blood were spiked with doses of each agent such that the gadolinium agents and the iodine agents reached concentrations of 0.5 mM and 12 mg iodine/mL, respectively. Subsequently, 12 assays were reexamined using 1/2 and 1/4 of these CA concentrations. The results were assessed statistically by a paired Student’s -test. Results. Iodixanol produced a negative interference on the bicarbonate (= 0.011), lactate dehydrogenase ( < 0.0001), and zinc ( = 0.0034) assays and a positive interference on the albumin ( = 0.0062), calcium ( < 0.0001), ionized calcium ( = 0.0086), iron ( < 0.0001), and potassium ( = 0.0003) assays.
    [Show full text]
  • Immediate Reactions Following Iodinated Contrast Media Injection: a Study of 38 Cases
    European Journal of Radiology 77 (2011) 495–501 Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Immediate reactions following iodinated contrast media injection: A study of 38 cases Pascale Dewachter a,∗, Dominique Laroche b,1, Claudie Mouton-Faivre c,2, Evelyne Bloch-Morot d,3, Jean-Pierre Cercueil e,4, Liliane Metge f,5, Marie-France Carette g,6, Marie-Claude Vergnaud h,7, Olivier Clément i,8 a Service d’Anesthésie-Réanimation Chirurgicale & SAMU de Paris, Hôpital Necker-Enfants Malades, AP-HP, Université Paris-Descartes, 149 Rue de Sèvres, 75015 Paris, France b Service de Biophysique, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France c Pôle d’Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire-Hôpital Central, Avenue du Maréchal de Lattre de Tassigny, Nancy, France d Service de Médecine Interne, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, Paris, France e Département d’Imagerie Medicale, Centre Hospitalier Universitaire, Hôpital du Bocage, 2, Boulevard du Maréchal de Lattre de Tassigny, Dijon, France f Département d’Imagerie Médicale, Centre Hospitalier Universitaire Caremeau, Place du Pr Robert Debré, Nîmes, France g Service de Radiologie, Hôpital Tenon, 4 Rue de la Chine, Paris, France h Service de Médecine Polyvalente, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France i Service de Radiologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, 20 Rue Leblanc, Paris, France article info abstract Article history: Objectives: To investigate the pathomechanisms involved in cases of immediate hypersensitivity reactions Received 2 August 2009 occurring after the administration of iodinated contrast media.
    [Show full text]
  • Investigating the Environmental Fate of Iodinated X-Ray Contrast
    Investigating the Environmental Fate of Iodinated X-ray Contrast Media in the Urban Water Cycle: Identification, Characterization, and Occurrence of Biotransformation Products Dissertation Zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaft Fachbereich 3: Mathematik/Naturwissenschaften Universität Koblenz-Landau Vorgelegt am 28.05.2010 von Jennifer Lynne Kormos, M.Sc. geb. am. 13.11.1979 in St. John’s, Canada Referent: PD Dr. Thomas A. Ternes Koreferent: Prof. Dr. Joachim Scholz 2 Acknowledgments This thesis is the result of a collaborative effort from many people! First of all I would like to thank the Marie Curie Research Training Network KEYBIOEFFECTS for funding this research and more importantly providing opportunities for me to network with other graduate students and research scientists in a number of scientific disciplines within Europe and internationally. I would like to thank and acknowledge Dr. Thomas Ternes, my supervisor, or as they say in German my “Doktor Vater,” for giving me the opportunity to complete my PhD in his research group at the Federal Institute of Hydrology (Bundesanstalt für Gewässerkunde, BfG). It was an honour for me to work with an internationally-known researcher investigating the occurrence and fate of emerging organic micropollutants. His dedication, guidance, support, enthusiasm and extensive knowledge are just a few of his qualities that helped me to strive in completing my PhD degree. I would like to thank Prof. Dr. Joachim Scholz for agreeing to be one of the evaluators of my PhD thesis and the University of Koblenz-Landau for allowing me to defend my dissertation in the Department of Chemistry.
    [Show full text]